Brief ReportBrief Communication
Open Access

The clinical features of patients concurrent with Guillain-Barré syndrome and myasthenia gravis

Junliang Yuan, Juan Zhang, Bingwei Zhang and Wenli Hu
Neurosciences Journal January 2018, 23 (1) 66-70; DOI: https://doi.org/10.17712/nsj.2018.1.20170209

Article Figures & Data

Figures

Tables

  • Table 1

    The demographic data and characteristics of comorbid AIDP and MG (8 cases).

    CharacteristicsCase 1Case 2Case 3Case 4Case 5Case 6Case 7Case 8
    Author (yr)Regev I(1982)Regev I(1982)Carlander B(1991)Kizilay F(2008)Kung SL(2009)Wang JY(2011)Hsieh MY(2013)Zhang J(2013)
    PopulationIsraelIsraelFranceUSATaiwan/ChinaChinaTaiwan/ChinaChina
    GenderFFMMFMFM
    Age6029455236421773
    Preceding factors--++++++
    Clinical characteristicsLimb weakness, areflexia, ptosis, dyspnea, facial palsyLimb weakness, areflexia, facial palsy, dysphagia, ptosis, dyspneaLimb weakness, areflexia, facial palsy, ptosis, respiratory failureLimb weakness, areflexia, ptosis, ophthalmoplegiaLimb weakness, areflexia, ptosis, ophthalmoplegia, facial palsy, dysarthria, respiratory failureLimb weakness, areflexia, ptosis, ophthalmoplegiaLimb weakness, areflexia, ptosis, dysphagia, dysarthria, respiratory failureMild dyspnea, mild dysarthria and dysphagia, intubation, ptosis and weakness,
    Albumino-cytologic dissociation--+++++-
    Nerve conduction++++++++
    RNS--++++++
    Anti-AChR antibody++++++++
    Anti-GQ1b antibody--------
    Edrophonium chloride++++--++
    Treatment--PyridostigmineIVIG, steroids, pyridostigminePlasma exchange, Pyridostigmine, steroidsIVIG, steroids, pyridostigmine, azathioprinumIVIG, steroids, pyridostigminepyridostigmine, IVIG, methylprednisolone
    Thymectomy-++---+-
    Prognosis--631004

    • MG - Myasthenia gravis, AIDP - Acute inflammatory demyelinating polyradiculoneuropathy, IVIG - intravenous immunoglobulin, RNS - repetitive nerve stimulation, Functional outcome was ranked according to the adopted scale by Hughes: 0 healthy; 1 minor symptoms or signs, able to run; 2 able to walk >5 m without assistance, but unable to run; 3 able to walk >5 m with assistance; 4 bed- or chair-bound; 5 requiring assisted ventilation for at least part of the day; and 6 dead. “+” indicates the patient had precipitating factors from infectious disease. “-” indicates the patient did not have precipitating factors from infectious disease. As for the other parameters, “+” indicates positive findings, and “-” indicates negative findings.

  • Table 2

    The demographic data and characteristics of comorbid MFS and MG (5 cases).

    characteristicsCase 1Case 2Case 3Case 4Case 5
    Author (yr)Mak W(2005)Silverstein MP(2008)Lau KK(2009)Tanaka Y(2016)Our case
    PopulationHong Kong/ChinaUSAHong Kong/ChinaJapanChina
    GenderMMFFM
    Age4043846972
    Preceding factors+-+--
    Clinical characteristicsLimb weakness, areflexia, ptosis, ophthalmoplegiaAtaxia, areflexia, ophthalmoplegia, ptosisweakness, areflexia, ptosis, ophthalmoplegia, dysphagia, dysarthria, respiratory failureAcute bilateral ptosis, ophthalmoplegia, ataxic gait, and areflexiaAcute bilateral ptosis, ophthalmoplegia, diplopia
    Albumino-cytologic dissociation+-+-+
    Nerve conduction+-+-+
    RNS-++++
    Anti-AChR antibody+++++
    Anti-GQ1b antibody+--++
    Edrophonium chloride
    Treatmentplasmapheresis, pyridostigmine-Pyridostigmine, IVIGIVIG, Steroidpyridostigmine, IVIG
    Thymectomy----+
    Prognosis10010

    • M- Male, F - Female, MG - Myasthenia gravis, MFS - Miller Fisher Syndrome, IVIG - intravenous immunoglobulin, RNS - repetitive nerve stimulation, Functional outcome was ranked according to the adopted scale by Hughes: 0, healthy; 1, minor symptoms or signs, able to run; 2, able to walk >5 m without assistance, but unable to run; 3, able to walk >5 m with assistance; 4, bed- or chair-bound; 5, requiring assisted ventilation for at least part of the day; and 6, dead. “+” indicates the patient had precipitating factors from infectious disease.”-” indicates the patient did not have precipitating factors from infectious disease. As for the other parameters, “+” indicates positive findings, and “-” indicates negative findings

  • Table 3

    The demographic data and characteristics of AMSAN (1 case) and AMAN (1 case).

    CharacteristicCase 1Case 2
    Author (yr)Farah R(2005)Kraus J(2007)
    PopulationIsraelCaucasian
    GenderMM
    Age71(AMSAN)65(AMAN)
    Preceding factors++
    Clinical characteristicsLimb weakness, areflexia, ptosis, dysarthria, dysphagia, respiratory failureLimb weakness, areflexia, ptosis, dysarthria, dysphagia, respiratory failure
    Albumino-cytologic dissociation++
    Nerve conduction++
    RNS-+
    Anti-AChR antibody-+
    Anti-GQ1b antibody-+
    Edrophonium chloride-+
    Treatmentplasmapheresis, IVIGIVIG, corticosteroids, pyridostigmine, azathioprine
    Thymectomy--
    Prognosis62

    • M- Male, F - Female, yr - Year, MG - Myasthenia gravis, AMAN - acute motor axonal neuropathy, AMSAN - acute motor-sensory axonal neuropathy, IVIG - intravenous immunoglobulin, RNS - repetitive nerve stimulation. Functional outcome was ranked according to the adopted scale by Hughes: 0, healthy; 1, minor symptoms or signs, able to run; 2, able to walk >5 m without assistance, but unable to run; 3, able to walk >5 m with assistance; 4, bed- or chair-bound; 5, requiring assisted ventilation for at least part of the day; and 6, dead. “+” indicates the patient had precipitating factors from infectious disease.”-” indicates the patient did not have precipitating factors from infectious disease. As for the other parameters, “+” indicates positive findings, and “-” indicates negative findings

Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section